Unlock instant, AI-driven research and patent intelligence for your innovation.

Compound anesthetic drug

A compound anesthesia and anesthesia technology, which is applied in the direction of anesthetics, drug combinations, and active ingredients of hydroxyl compounds, can solve the problems of decreased clearance rate of propofol, delayed awakening, and suppression of adrenal cortex function, so as to reduce the content of anesthetics and reduce Discomfort, effects that promote narcotic effects

Pending Publication Date: 2019-01-11
韩伟
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the drug also has side effects. The most obvious one is respiratory and circulatory inhibition during anesthesia induction. Due to the dual effects on peripheral vasodilation and direct cardiac inhibition, especially when the induction dose is used, it has a significant inhibitory effect on the cardiovascular and circulatory system. Manifested as hypotension, even if there is no history of relevant cardiovascular disease, a small dose of propofol can induce a 25-40% drop in systolic blood pressure, and the inhibitory effect is more pronounced with increasing doses and drug concentrations in the blood, and often seen with apnea
These shortcomings have greatly restricted the clinical application and development of propofol. For example, in the elderly population, as the age grows, the brain will become more sensitive to propofol, and the clearance rate of propofol will also decrease significantly. May lead to problems such as insufficient depth of anesthesia and delayed recovery due to changes in hemodynamics
Another example is that etomidate is widely used in clinical anesthesia because of its unique advantages, and it is suitable for patients with cardiovascular, respiratory, intracranial hypertension and other diseases who are not suitable for other drugs, such as the elderly. There are side effects such as convulsions, severe postoperative nausea and vomiting, and suppression of adrenal cortex function
[0004] Although the use of some drugs before surgery can reduce the dosage of anesthetic drugs, such as midazolam, narcotic analgesics, β receptor blockers, calcium ion channel blockers, melatonin, etc., but at the same time it also faces problems such as affecting psychomotor Functionality, sleep patterns, hemodynamics, and cost

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound anesthetic drug
  • Compound anesthetic drug
  • Compound anesthetic drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0018] As a preferred embodiment of the present invention, the amino acid is selected from one or more of arginine, lysine, and histidine.

[0019] As a preferred embodiment of the present invention, the pH of the compound anesthetic is greater than 6.5.

[0020] As a preferred embodiment of the present invention, the amine-based drug pseudoephedrine, aminophylline tablets, epinephrine, and hydrochlorothiazide.

[0021] As a preferred embodiment of the present invention, the mass content of the amino drug is 0.1-1% of the compound anesthetic drug.

[0022] As a preferred embodiment of the present invention, the clinical anesthetic drug is propofol, and the parts by weight of each active component are: 0.1-1 part of amine-based drug, 2-5 parts of acetylsalicylic acid, 2-10 parts of amino acid , 10-15 parts of vitamin C, 30-40 parts of propofol.

[0023] As a preferred embodiment of the present invention, the content of each component of etomidate as the clinical anesthetic dr...

Embodiment 1

[0032] Embodiment 1, propofol is the joint use situation of anesthetic

[0033] 1. Experimental animals

[0034] Clean grade C57BL / 6J, male, 6-7 weeks old, weighing 20±2g, purchased from Beijing Weitong Lihua Experimental Animal Company; room temperature 23±2°C, fluorescent lighting 7:00-19:00. Before the official start of the experiment, the mice were allowed to adapt to the laboratory environment for at least 1 week, free to eat and drink, and the experiment was carried out at a fixed time every day (10:00-12:00), and the laboratory environment was kept quiet.

[0035] 2. Use of drugs

[0036] Propofol, vitamin C, lysine, pseudoephedrine, acetylsalicylic acid.

[0037] 3. method

[0038] Injection of drugs to establish mouse propofol general anesthesia induction model, all drugs were administered by intraperitoneal injection, each mouse was injected with a dose of 2.7mg / kg according to body weight, and randomly divided into 1-18 groups.

[0039] 4. Observe and record i...

Embodiment 2

[0047] Embodiment 2, etomidate is the combined use situation of anesthetic

[0048] 1. Experimental animals

[0049] Clean grade C57BL / 6J, male, 6-7 weeks old, weighing 20±2g, purchased from Beijing Weitong Lihua Experimental Animal Company; room temperature 23±2°C, fluorescent lighting 7:00-19:00. Before the official start of the experiment, the mice were allowed to adapt to the laboratory environment for at least 1 week, free to eat and drink, and the experiment was carried out at a fixed time every day (10:00-12:00), and the laboratory environment was kept quiet.

[0050] 2. Drug use

[0051] Etomidate, Vitamin C, Arginine, Aminophylline Tablets, Acetylsalicylic Acid.

[0052] 2. Method

[0053] Injecting drugs to establish etomidate general anesthesia induction model in mice, all drugs were administered by intraperitoneal injection, and each mouse was injected with a dose of 2.7mg / kg according to body weight, and randomly divided into 1-18 groups.

[0054] 3. Method

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a compound anesthetic drug. The active ingredients of the compound anesthetic drug include an amino drug, acetylsalicylic acid, amino acid, vitamin C and clinical anesthetic drug. The clinical anesthetic drug is propofol, etomidate and ketamine. The clinical anesthetic drug and the amino drug, acetylsalicylic acid, amino acid and vitamin C are used together, so that the content of anesthetic drugs is reduced, thereby achieving the purpose of reducing side effects, especially damage to brain, heart, kidney and other important organs, and the compound anesthetic drug ofthe invention overcomes the side effects of lowering blood pressure of patients in the use process of traditional anesthetic drugs.

Description

technical field [0001] The invention belongs to anesthetics in the field of medicine, in particular to a compound anesthetic. Background technique [0002] Anesthetics refer to drugs that can cause temporary and reversible loss of consciousness and pain in the whole body or parts of the body. Root anesthetics are divided into general anesthetics and local anesthetics. General anesthetics inhibit the cerebral cortex from shallow to deep, making people lose their consciousness. Local anesthesia can stabilize the membrane potential of the nerve or reduce the permeability of the membrane to sodium ions, block the conduction of nerve impulses, and act as a local anesthetic. At present, although there are many types of clinical anesthetics and each has its own strengths, each anesthetic cannot fully meet the ideal standards of clinical anesthesia. [0003] Anesthesia drugs are necessary drugs for clinical operations, including propofol, etomidate, ketamine, thiopental sodium, e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/05A61K31/137A61K31/22A61K31/4164A61K31/136A61K31/549A61K31/375A61P23/00
CPCA61P23/00A61K31/05A61K31/136A61K31/137A61K31/22A61K31/375A61K31/4164A61K31/549A61K2300/00
Inventor 韩伟
Owner 韩伟